Pfizer Inc and BioNTech SE received U.S. regulatory authorization for their COVID-19 vaccine on Friday, making it the first inoculation against the new coronavirus to get a regulatory green light in the United States.
The following is what we know about the race to deliver vaccines to help end the coronavirus pandemic that has killed 1.59 million people worldwide:
WHO IS FURTHEST ALONG?
U.S. drugmaker Pfizer and German partner BioNTech are the coronavirus vaccine trailblazers.
On Nov. 18, they became the first in the world to release full late-stage trial data. Britain was the first to approve the shot for emergency use on Dec. 3, followed by Canada on Dec. 9 and the U.S. Food and Drug Administration (FDA) on Dec. 11.
The European Medicines Agency (EMA) is due to complete its review of the shot by Dec. 29 and India is accelerating its review.
WHO WILL BE NEXT?
U.S. pharmaceutical company Moderna is ahead of the pack at this point. It was next to release full data analysis for a late-stage trial on Nov. 30, with its vaccine showing a 94.1% efficacy rate. FDA advisers are due to review it on Dec. 17 and the EMA will do so by Jan. 12.
WHO ELSE IS IN THE RUNNING?
Britain's AstraZeneca is seeking approval for its vaccine in Britain after announcing interim late-stage trial data on Nov. 23. It had an average efficacy rate of 70% and as much as 90% for a subgroup of trial participants who got a half dose first, followed by a full dose.
However, it is not clear how the regulator will deal with the different dosages in the efficacy data in its assessment. While India is conducting an accelerated review, it has asked for more data. AstraZeneca is also in discussions with the EMA, which is conducting a rolling review of the vaccine.
U.S. drugmaker Johnson & Johnson plans to deliver trial data this year, or early in 2021, teeing it up for U.S. authorization in February if its shot is effective. It reduced the enrollment target for its clinical trial to 40,000 volunteers from 60,000 on Dec. 9, potentially speeding results which are tied to how quickly participants become infected.
U.S. firm Novavax is running a late-stage trial in Britain with data due in the first quarter of 2021. It expects to start a large-scale trial in the United States this month.
France's Sanofi and Britain's GlaxoSmithKline, however, announced a setback on Dec. 11 in their attempts to develop a vaccine. The drugmakers said it showed an insufficient immune response in older people in mid-stage trials and that they would start a new study in February.
WHAT HAPPENS IN THE TRIALS?
The companies typically test their vaccines against a placebo - typically saline solution - in healthy volunteers to see if the rate of COVID-19 infection among those who got the vaccine is significantly lower than in those who received the dummy shot.
HOW ARE VOLUNTEERS INFECTED?
The trials rely on subjects becoming naturally infected with COVID-19, so how long it takes to generate results largely depends on how pervasive the virus is where trials are being conducted. Each drugmaker has targeted a specific number of infections to trigger a first analysis of their data.
HOW WELL ARE THE VACCINES SUPPOSED TO WORK?
The World Health Organization ideally wants to see at least 70% efficacy. The FDA wants at least 50% - which means there must be at least twice as many infections among volunteers who received a placebo as among those in the vaccine group. The EMA has said it may accept a lower efficacy level.
WHAT ABOUT RUSSIA AND CHINA?
While Pfizer's shot was the first to be rolled out following the publication of full Phase III trial data, Russia and China have been inoculating their citizens for months with several different vaccines still undergoing late-stage trials.
Russia said on Nov. 24 that its Sputnik V vaccine, developed by the Gamaleya Institute, was 91.4% effective based on interim late-stage trial results. It started vaccinations in August and has inoculated more than 100,000 people so far.
AstraZeneca said on Dec. 11 that it would test a combination of its vaccine with one of Sputnik V's two components to try to boost the efficacy of the shot it is developing with Oxford University.
China launched an emergency use programme in July aimed at essential workers and others at high risk of infection. It has vaccinated about one million people as of mid-November using at least three shots - two developed by the state-backed China National Biotec Group (CNBG) and one by Sinovac Biotech.
Sinovac said on Nov. 18 that mid-stage trial results showed its CoronaVac shot triggered a quick immune response and interim data from its late stage trial could come this year.
The Butantan Institute, a Brazilian biomedical centre, is producing CoronaVac and aims to make 1 million doses a day ahead of a vaccine campaign to be launched late January.
The United Arab Emirates, meanwhile, said on Dec. 9 that one of the CNBG vaccines was 86% effective based on interim results from a late-stage trial in the Gulf Arab state.
Reuters
Sat Dec 12 2020
A nurse administers the Pfizer/BioNTech COVID-19 vaccine to a man at a vaccination centre, on the first day of the largest immunisation programme in the British history, in Cardiff, Wales, Britain Dec 8, 2020. REUTERSpic
Pelaksanaan mekanisma levi pelbagai peringkat (MLTM) dijangka bermula Januari 2025
Mekanisma levi pelbagai peringkat (MLTM) dijangka dilaksanakan pada Januari hadapan, selepas perinciannya dimuktamadkan dan diluluskan Jemaah Menteri, kata Menteri Sumber Manusia, Steven Sim.
Portal UP_TVET bertujuan untuk memudahkan proses permohonan
Saluran permohonan untuk mengikuti kursus Pendidikan dan Latihan Teknikal dan Vokasional (TVET) yang dahulunya mengelirukan kini dibuat melalui satu saluran tunggal iaitu menerusi portal Unit Pengambilan TVET atau singkatannya UP_TVET yang dibangunkan oleh Kementerian Sumber Manusia (KESUMA).
Menurut Timbalan Perdana Menteri, Datuk Seri Ahmad Zahid Hamidi,penggunaan saluran tunggal UP_TVET yang fleksibel dengan mengambil kira keperluan pelbagai syarat masuk merupakan satu inisiatif untuk membuka ruang seluasnya kepada rakyat Malaysia untuk menyertai program TVET.
Menurut Timbalan Perdana Menteri, Datuk Seri Ahmad Zahid Hamidi,penggunaan saluran tunggal UP_TVET yang fleksibel dengan mengambil kira keperluan pelbagai syarat masuk merupakan satu inisiatif untuk membuka ruang seluasnya kepada rakyat Malaysia untuk menyertai program TVET.
Kerajaan digesa bawa Mala pulang dari penjara Nepal
Kerajaan didesak untuk membawa pulang seorang rakyat Malaysia yang meringkuk di penjara Nepal atas kesalahan Imigresen.
Jemaah lega dapat luah perasaan di Ranting Hati
Jemaah haji Malaysia melahirkan rasa lega kerana berpeluang meluahkan perasaan sejak tiba di Tanah Suci menerusi tulisan terapi naratif yang menghasilkan Ranting Hati, satu inisiatif terbaharu diperkenalkan oleh Unit Kaunseling Tabung Haji (TH) sebagai platform menangani cabaran sebagai tetamu Allah sepanjang operasi musim ini.
Proses penggapungan kapal ambil masa 21 jam
Kapal berdaftar di Singapura, Dali yang melanggar struktur Jambatan Francis Scott Key di Baltimore, Maryland yang kemudiannya runtuh, mempunyai klasifikasi yang sah dan sijil berkanun yang meliputi integriti struktur kapal dan fungsi peralatannya. Penguasa Maritim dan Pelabuhan Singapura (MPA) berkata kapal kargo itu juga telah menjalani dua pemeriksaan yang diluluskan oleh dua pelabuhan asing pada Jun dan September 2023 dengan klasifikasi dan tinjauan berkanun seterusnya dijangka pada Jun 2024.
Iran berkabung tiga hari
Iran memulakan tempoh berkabung tiga hari susulan kematian Presidennya, Ebrahim Raisi yang terlibat dalam nahas helikopter pada Ahad yang turut mengorbankan Menteri Luarnya Hossein Amirabdollahian.Rakyatnya menyatakan kesedihan terhadap pemergian pemimpin mereka yang dikatakan berjasa dalam memelihara tembok keselamatan negara dari peperangan di rantau bergolak itu.
Ebrahim Raisi, Hossein Amir-Abdollahian individu penting perjuang isu Palestin
Presiden Iran, Ebrahim Raisi dan menteri luarnya, Hossein Amir-Abdollahian disifatkan sebagai antara individu penting dalam usaha masyarakat antarabangsa memperjuangkan isu Palestin.
Kerajaan jamin bawa pulang pegawai perubatan terkandas di Rafah
Kerajaan memberi jaminan akan membawa pulang pegawai perubatan di bawah MERCY yang terkandas di Rafah, Gaza.
Israel sekal laluan darat, situasi bertambah buruk
Sekatan Israel ke atas laluan darat melumpuhkan kemasukkan bekalan kemanusian ke Gaza dan dijangka memburukkan lagi situasi semasa di Gaza.
Netanyahu berdepan penolakan dunia, menteri dalam kabinet perang sendiri - Penganalisis
Pensyarah Kolej PERMATA Insan, Universiti Sains Islam Malaysia (USIM), Dr. Abdel Rahman Ibrahim berkata wajah sebenar Perdana Menteri Israel, Benjamin Netanyahu, yang dahagakan darah kini telah terdedah dan tidak lagi dapat menutup kepalsuan yang cuba dipaksakan kepada dunia. Jelasnya, Netanyahu bukan sahaja berdepan penolakan masyarakat antarabangsa bahkan juga tentangan dari dalam kebinet perangnya sendiri.
Suruhanjaya Eropah luluskan vaksin COVID-19 versi terkini
Suruhanjaya Eropah sudah meluluskan versi terkini vaksin COVID-19 yang dibangunkan oleh BioNTech-Pfizer.
Kempen MyPELINDUNG didik masyarakat terus perangi COVID-19
Meskipun Malaysia telah mencapai kemajuan ketara, namun virus COVID-19 tetap kekal sebagai satu kebimbangan kesihatan.
Puting beliung musnahkan gudang utama Pfizer
Syarikat farmaseutikal Pfizer mengesahkan bahawa kompleks tersebut telah rosak akibat puting beliung yang berlaku dekat Rocky Mount.
Belgium akan musnahkan hampir 6 juta vaksin COVID-19 yang luput
Belgium tidak boleh menggunakan lagi lebihan vaksin asli dan 2.6 juta dos Moderna dan 3.3 juta dos Pfizer akan dimusnahkan secepat mungkin.
WEF2023: Pfizer umum penjualan tanpa untung kepada negara miskin
Ini termasuk ubat luar paten, menjadikan jumlah keseluruhan produk yang ditawarkan kepada lebih 500 jenis.
Vaksin COVID-19: AS setuju cadangan dos penggalak kepada 12 tahun ke atas
CDC dijangka menerima pakai cadangan itu, sebagai langkah sebelum suntikan boleh dimulakan.
Moderna saman Pfizer, BioNTech kerana tiru paten
Moderna mendakwa, kedua-dua syarikat itu meniru teknologi yang dihasilkannya sejak sekian lama sebelum pandemik bermula.
COVID-19: Singapura beri suntikan dos penggalak kepada kanak-kanak berusia 5 hingga 11 tahun pada suku keempat
Kementerian Kesihatan sudah menerima cadangan yang dikemukakan Jawatankuasa Pakar mengenai Vaksinasi COVID-19 (EC19V).
COVID-19: Vaksin Pfizer, Moderna lulus untuk kanak-kanak 6 bulan ke 5 tahun
Dengan kelulusan ini, sekitar 18 juta kanak-kanak dalam kumpulan umur berkenaan layak untuk menerima vaksin.
PICKids: Tiada lagi vaksin Pfizer, Sinovac untuk kanak-kanak selepas 31 Mei - ProtectHealth
Sebelum ini Kementerian Kesihatan Malaysia (KKM) memutuskan untuk melanjutkan tarikh akhir pemberian vaksin PICKids dari 15 Mei kepada 31 Mei.